Study of HyQvia for Adults with CIDP in Routine Care
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study looks at how well HyQvia works for adults with CIDP in everyday medical practice. It includes people who are already using HyQvia or are switching to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) by a doctor.
- Your CIDP symptoms have been stable for at least 12 weeks.
- You are either planning to switch to HyQvia within 6 weeks, or you have already started HyQvia in the last 6 weeks.
- You are willing to follow study procedures and attend scheduled assessments.
- You are not pregnant or breastfeeding, and you have no known allergy to HyQvia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
This study tests whether a drug called obinutuzumab can help people with chronic inflammatory demyelinating polyradiculoneuropathy (a condition where the immune system attacks the nerves, causing weakness and numbness). The drug aims to reduce the immune attack and improve symptoms.
This study looks at how HyQvia (an immune-boosting medicine given under the skin) is used in real life for adults with multiple myeloma and secondary immune problems. It may help doctors understand what works best and how patients do when HyQvia is used routinely.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This study uses ultrasound to look at nerves in people with CIDP to help guide treatment. It aims to see if ultrasound can help doctors choose the best therapy for each person.
This study looks at how well current treatments work for people with CIDP (a nerve condition causing weakness). It tracks symptoms and daily function over time to help doctors understand which treatments may work best.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.